New York-based pharmaceuticals giant Pfizer has announced it will begin production of a component of its Covid-19 vaccine at its Grange Castle facility in west Dublin, Ireland, by the end of 2021. The company will invest $40m to produce the mRNA drug substance for the BioNTech vaccine and create 75 jobs.
In a statement, Pfizer explained that the move is part of plans with its partner, Germany-based BioNTech, to enhance the vaccine’s supply chain. These plans include expanding existing facilities, adding more suppliers, and contracting manufacturers around the world to produce the vaccine.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company’s vice-president for global supply, Dr Paul Duffy, said: “This is a very significant moment for Ireland and for our Grange Castle site. We are immensely proud to be able to play a part in manufacturing Pfizer’s Covid-19 vaccine.”
Pfizer previously announced plans to invest $365.5m €300m) in its Irish operations across Grange Castle, Newbridge and Ringaskiddy in November 2020.
